Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion type Assertion NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_head.
- NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_provenance.
- NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion evidence source_evidence_literature NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_provenance.
- NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion SIO_000772 23911281 NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_provenance.
- NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion wasDerivedFrom befree-20150227 NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_provenance.
- NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion wasGeneratedBy ECO_0000203 NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_provenance.